How long does it take for Erdafitinib to start inhibiting cancer cell proliferation?

Erdafitinib is an oral FGFR (fibroblast growth factor receptor) kinase inhibitor mainly used to treat advanced or metastatic urothelial carcinoma harboring FGFR gene mutations or fusions. As a targeted therapy drug, erdafitinib blocks the proliferation and growth of cancer cells by selectively inhibiting the FGFR signaling pathway. Regarding its onset of action, patients and clinicians are generally concerned about how quickly a drug can inhibit cancer cells.

Generally, the inhibitory effects of erdafitinib become apparent within a few days after patients start taking the drug. Clinical studies have shown that some patients can observe a significant reduction in tumor burden and improvement in symptoms within a few weeks after taking erdafitinib. This rapid onset of action is mainly attributed to its efficient inhibition of the FGFR signaling pathway, which prevents tumor cells from continuing to rely on this pathway for growth, thereby achieving the effect of inhibiting and shrinking tumors.

However, the specific onset of effect varies between individual patients. The molecular characteristics of the tumor, the progression stage of the disease, the patient's physical condition and medication compliance will all affect the therapeutic effect and onset speed of erdafitinib. Some patients may take longer to see significant effects, so regular imaging and clinical evaluation are important to accurately determine the therapeutic response to the drug.

In general, erdafitinib, as a targeted drug, usually begins to inhibit cancer cell proliferation within days to weeks after administration. Patients should remain patient during the treatment process, use medication strictly in accordance with the doctor's instructions, and conduct regular reviews to ensure timely detection of curative effects and adjustments to the treatment plan to achieve the best treatment effect.

Reference materials:https://www.drugs.com